Exelon provides clinically meaningful benefits in cognition and global functioning for patients with mild-to-moderate dementia.

Symptomatic Improvement in Cognitive and Functional Domains

Clinical trials demonstrate that Exelon significantly improves cognitive performance, as measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), and global clinical status, as assessed by the Clinician’s Interview-Based Impression of Change (CIBIC-Plus), in patients with mild-to-moderate Alzheimer’s disease and Parkinson’s disease dementia. Higher doses within the recommended range are associated with greater efficacy. However, Exelon does not modify the underlying disease progression, and its benefit may diminish as neurodegeneration advances. The therapeutic effect is most pronounced during the early and middle stages of dementia.